722.57
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$719.39
Offen:
$719.23
24-Stunden-Volumen:
2.78M
Relative Volume:
0.69
Marktkapitalisierung:
$684.81B
Einnahmen:
$49.00B
Nettoeinkommen (Verlust:
$11.11B
KGV:
58.79
EPS:
12.29
Netto-Cashflow:
$-1.27B
1W Leistung:
+1.03%
1M Leistung:
-18.37%
6M Leistung:
-9.15%
1J Leistung:
-10.96%
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
LLY
Lilly Eli Co
|
722.57 | 642.06B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
153.58 | 367.19B | 89.33B | 21.81B | 18.57B | 8.99 |
![]()
ABBV
Abbvie Inc
|
185.62 | 322.44B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
112.58 | 222.20B | 53.22B | 12.86B | 14.85B | 6.39 |
![]()
NVO
Novo Nordisk Adr
|
69.46 | 302.90B | 43.59B | 15.04B | 10.74B | 3.3766 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-12-10 | Fortgesetzt | BofA Securities | Buy |
2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
2024-10-17 | Eingeleitet | Bernstein | Outperform |
2024-09-13 | Fortgesetzt | Citigroup | Buy |
2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
2023-10-20 | Fortgesetzt | UBS | Buy |
2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
2023-07-26 | Bestätigt | Citigroup | Buy |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-05-24 | Bestätigt | BofA Securities | Buy |
2023-05-24 | Bestätigt | UBS | Buy |
2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-03-06 | Eingeleitet | Jefferies | Hold |
2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
2022-09-22 | Hochstufung | UBS | Neutral → Buy |
2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
2021-12-17 | Eingeleitet | Goldman | Neutral |
2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
2021-12-16 | Bestätigt | BofA Securities | Buy |
2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
2021-07-27 | Fortgesetzt | Truist | Buy |
2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
2020-09-29 | Eingeleitet | Berenberg | Hold |
2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
2020-04-21 | Herabstufung | UBS | Buy → Neutral |
2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-02-06 | Eingeleitet | Mizuho | Neutral |
2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
2019-05-28 | Eingeleitet | Goldman | Buy |
2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
2019-03-12 | Eingeleitet | JP Morgan | Overweight |
2019-01-23 | Eingeleitet | UBS | Buy |
2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
2018-10-09 | Eingeleitet | Guggenheim | Buy |
2018-10-01 | Bestätigt | SunTrust | Buy |
2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly (LLY) Bulls Eye $1,000 Stock Price Target as GLP-1 Alpha Bandwagon Rolls On - TipRanks
Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions - Eli Lilly and Company
Was Jim Cramer Right About Eli Lilly and Company (LLY)? - Insider Monkey
UBS maintains Eli Lilly stock with $1,050 target - Investing.com
Novo Is Losing Steam. Can It Oh, Oh, Oh, Obtain New Grounding? - Investor's Business Daily
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run - MarketBeat
Eli Lilly (LLY) Gains Upper Hand in Weight-Loss Drug Market | LL - GuruFocus
Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.
Ochre Bio appoints ex- Eli Lilly and AstraZeneca VP as Non-Executive Director - Health Tech World
The weight loss war: Who is winning out between Novo-Nordisk and Eli Lilly? - Shares Magazine
‘Start a Position’ in Eli Lilly Stock (LLY), Says Jim Cramer - TipRanks
Is Eli Lilly And Company Stock Underperforming The Dow? - Barchart.com
Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer - Yahoo Finance
Lilly adds non-opioid painkiller to pipeline in $1B Siteone buyout - BioWorld MedTech
BMO reiterates Eli Lilly stock with $900 target on SiteOne deal - Investing.com
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy? - The Globe and Mail
Lilly seeks to expand pain pipeline with $1B acquisition - dailyjournal.net
Lilly to acquire biotech developing pain drugs - statnews.com
Reports: Lilly eyes Houston for new $5.9B manufacturing facility - Indianapolis Business Journal
Lilly to acquire SiteOne Therapeutics to expand pain pipeline - World Pharmaceutical Frontiers
Eli Lilly to expand pain portfolio with SiteOne acquisition - Cleanroom Technology
Jim Cramer Notes Eli Lilly (LLY) Stock is at a “Decent Level to Start a Position” - Insider Monkey
Lilly snags Peninsula non-opioid pain drug company for up to $1 billionSan Francisco Business Times - The Business Journals
Eli Lilly Commits $1B to Get Drug That Could Rival Vertex’s New Non-Opioid Pain Med - MedCity News
Lilly's Acquisition Of SiteOne Aims For Opioid AlternativesEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly Targets Pain Management Opportunity with SiteOne Therapeutics Acquisition - Insider Monkey
Eli Lilly Inks $1B Deal For Non-Opioid Pain-Drug Maker - Law360
Eli Lilly (LLY) Shows Strong Options Activity Amid Share Price Rise | LLY Stock News - GuruFocus
Eli Lilly to expand pain pipeline with $1bn SiteOne buyout - Pharmaceutical Technology
Eli Lilly to buy SiteOne for $1 billion with eye on non-opioid pain drug - Reuters
Eli Lilly’s Strategic Acquisition of SiteOne Therapeutics Bolsters Pain Management Portfolio and Supports Buy Rating - TipRanks
Eli Lilly (LLY) Expands into Pain Management Through Acquisition | LLY Stock News - GuruFocus
Eli Lilly (LLY) to Acquire SiteOne Therapeutics for $1 Billion - GuruFocus
Eli Lilly expands neuroscience pipeline with $1B SiteOne acquisition - Proactive financial news
Seven top pharmas posted revenue declines in Q1. The common thread? All are US firms - Fierce Pharma
Eli Lilly To Acquire SiteOne Therapeutics For Up To $1B To Advance Pain Management Pipeline: But Retail’s Unconvinced By Stocktwits - Investing.com India
Lilly to acquire SiteOne, enhancing non-opioid pain treatment options By Investing.com - Investing.com India
Lilly to acquire SiteOne, enhancing non-opioid pain treatment options - Investing.com Australia
Eli Lilly expands pain pipeline with acquisition of SiteOne Therapeutics By Investing.com - Investing.com Nigeria
Eli Lilly expands pain pipeline with acquisition of SiteOne Therapeutics - Investing.com
Eli Lilly (LLY) to Acquire SiteOne Therapeutics in $1 Billion De - GuruFocus
Eli Lilly’s SWOT analysis: stock poised for growth amid challenges - Investing.com
Eli Lilly to acquire privately held SiteOne - Yahoo
Eli Lilly & Co. (LLY) Acquires SiteOne Therapeutics - StreetInsider
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics | Eli Lilly and Company - Eli Lilly and Company
Lilly Makes $1B Bet on Next-Generation Pain Treatment: Key Details of SiteOne Acquisition Revealed - Stock Titan
Investment Case For Eli Lilly Still Weak, Despite Novo Nordisk's Struggle (NYSE:LLY) - Seeking Alpha
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Lilly's blood drive breaks site record - reporter.net
Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly - AOL.com
Eli Lilly (LLY) Considers New $5.9 Billion Plant in Houston, Texas - TipRanks
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):